Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
DOWNLOAD WHITEPAPER

Investment in Supply Chain Visibility Saves Costs

A risk-based approach to monitoring investigational medicinal products can help pharmaceutical companies improve supply chain efficiency, but to do this without compromising quality relies on fast access to comprehensive shipment data.

Using TSS' Cloud temperature monitoring solution CCIS and data loggers, GlaxoSmithKline has saved £4m annually.

Q: What does GSK’s risk-based approach to monitoring investigational medicinal products (IMP) entail, and why did you adopt it?

Director of supply chain logistics and IMP at GSKRob Montague said: "The regulators involved in EU good distribution practice (GDP), like many regulatory bodies, continue to evolve their thinking in the temperature monitoring and product exposure space. GSK has chosen to focus on quality for the patient as a key driver.

"Many companies apply the term 'risk-based approach’ to their decision not to monitor products in transit in certain lanes or at certain times of the year. At GSK, we’ve demonstrated that the vagaries of transportation can cause amazing excursions when logic dictates the shipment should be at low risk."



Download to find out more.

DOWNLOAD

Submit

DOWNLOAD WHITEPAPER

Investment in Supply Chain Visibility Saves Costs

A risk-based approach to monitoring investigational medicinal products can help pharmaceutical companies improve supply chain efficiency, but to do this without compromising quality relies on fast access to comprehensive shipment data.

Using TSS' Cloud temperature monitoring solution CCIS and data loggers, GlaxoSmithKline has saved £4m annually.

Q: What does GSK’s risk-based approach to monitoring investigational medicinal products (IMP) entail, and why did you adopt it?

Director of supply chain logistics and IMP at GSKRob Montague said: "The regulators involved in EU good distribution practice (GDP), like many regulatory bodies, continue to evolve their thinking in the temperature monitoring and product exposure space. GSK has chosen to focus on quality for the patient as a key driver.

"Many companies apply the term 'risk-based approach’ to their decision not to monitor products in transit in certain lanes or at certain times of the year. At GSK, we’ve demonstrated that the vagaries of transportation can cause amazing excursions when logic dictates the shipment should be at low risk."



Download to find out more.

DOWNLOAD

We just need a few more details

I have read and accept the terms and conditions and privacy policys.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.








Go Top